Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Rating of “Hold” from Brokerages

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) have been assigned a consensus rating of “Hold” from the twenty analysts that are currently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, fifteen have given a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $34.80.

SAGE has been the subject of several recent research reports. Truist Financial reduced their price target on Sage Therapeutics from $22.00 to $18.00 and set a “hold” rating for the company in a research report on Friday, April 26th. Scotiabank reduced their price target on Sage Therapeutics from $34.00 to $19.00 and set a “sector outperform” rating for the company in a research report on Thursday, April 18th. JPMorgan Chase & Co. reduced their price target on Sage Therapeutics from $28.00 to $23.00 and set an “overweight” rating for the company in a research report on Thursday, June 20th. Morgan Stanley boosted their target price on Sage Therapeutics from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 28th. Finally, Bank of America cut Sage Therapeutics from a “neutral” rating to an “underperform” rating and reduced their target price for the stock from $24.00 to $14.00 in a research report on Wednesday, April 17th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Lazard Asset Management LLC bought a new position in Sage Therapeutics during the 1st quarter valued at approximately $127,000. China Universal Asset Management Co. Ltd. raised its position in Sage Therapeutics by 353.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,937 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 5,406 shares during the last quarter. Virtu Financial LLC bought a new position in Sage Therapeutics during the 1st quarter valued at approximately $187,000. ProShare Advisors LLC raised its position in Sage Therapeutics by 9.0% during the 1st quarter. ProShare Advisors LLC now owns 13,713 shares of the biopharmaceutical company’s stock valued at $257,000 after purchasing an additional 1,130 shares during the last quarter. Finally, Quest Partners LLC bought a new position in shares of Sage Therapeutics in the 4th quarter worth approximately $261,000. Institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Price Performance

NASDAQ:SAGE opened at $10.90 on Wednesday. The business has a fifty day simple moving average of $11.99 and a two-hundred day simple moving average of $18.42. Sage Therapeutics has a 1 year low of $9.76 and a 1 year high of $50.19. The company has a market capitalization of $655.96 million, a P/E ratio of -1.30 and a beta of 0.92.

Sage Therapeutics (NASDAQ:SAGE) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.63) by ($0.17). The firm had revenue of $7.90 million during the quarter, compared to analysts’ expectations of $5.26 million. Sage Therapeutics had a negative return on equity of 56.81% and a negative net margin of 552.52%. The business’s quarterly revenue was up 139.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($2.46) earnings per share. As a group, analysts anticipate that Sage Therapeutics will post -6.46 earnings per share for the current year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.